Incyte (FRA:ICY) YoY EBITDA Growth : 184.45% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Incyte YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Incyte's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 184.45%.

Incyte's EBITDA per Share for the three months ended in Dec. 2023 was €1.19.

Incyte YoY EBITDA Growth Historical Data

The historical data trend for Incyte's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte YoY EBITDA Growth Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

220.40

-129.92

473.66

0.68

47.63

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															-22.74	-17.09	17.07	41.71	184.45

Incyte YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Incyte's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(3.732	-	2.528)	/	\| 2.528 \|
=	47.63 %

Incyte's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(1.189	-	0.418)	/	\| 0.418 \|
=	184.45 %

Incyte YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Incyte's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (FRA:ICY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (FRA:ICY) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (FRA:ICY) Headlines

No Headlines